Scholarlink

Aims <p>Next generation sequencing (NGS) represents the “holy grail” for the diagnostic algorithm for advanced solid tumors. In our experience, we commonly use our customized DNA-based NGS panel (namely, SiRe®). The aim of this study was to assess the efficiency of our customized DNA-based NGS panel in detecting molecular alterations in both tissue and liquid biopsy samples.</p> Methods <p>We retrospectively retrieved molecular data from our electronic archives of advanced stage solid tumor cases tested by our DNA-based NGS approach from January 2018 to December 2022. Almost all samples (2045/2173, 94.1%), including liquid biopsies, were analyzed with our DNA-based NGS approach. We also retrieved all relevant molecular data on other tested biomarkers.</p> Results <p>A total of n = 2173 advanced stage solid tumor patients were tested. Overall, at least one DNA-based alteration was detected in 52.7%, 66.6%, 87.6%, 68.8%, 46.7% of NSCLC ADC, CRC, GIST, melanoma, and breast cancer cases.</p> Conclusions <p>The present study has provided a real-world practice experience on the efficiency of applying DNA-based NGS analysis to both tissue and liquid biopsy samples in detecting actionable mutations in advanced stage solid tumor patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Pasquale Pisapia,
  • Antonino Iaccarino,
  • Caterina De Luca,
  • Francesco Pepe,
  • Gianluca Russo,
  • Mariantonia Nacchio,
  • Domenica Di Giovanni,
  • Domenico Cozzolino,
  • Floriana Conticelli,
  • Lucia Palumbo,
  • Claudia Scimone,
  • Gianluca Gragnano,
  • Maria Russo,
  • Maria Salatiello,
  • Elena Vigliar,
  • Claudio Bellevicine,
  • Giancarlo Troncone,
  • Umberto Malapelle

摘要

Aims

Next generation sequencing (NGS) represents the “holy grail” for the diagnostic algorithm for advanced solid tumors. In our experience, we commonly use our customized DNA-based NGS panel (namely, SiRe®). The aim of this study was to assess the efficiency of our customized DNA-based NGS panel in detecting molecular alterations in both tissue and liquid biopsy samples.

Methods

We retrospectively retrieved molecular data from our electronic archives of advanced stage solid tumor cases tested by our DNA-based NGS approach from January 2018 to December 2022. Almost all samples (2045/2173, 94.1%), including liquid biopsies, were analyzed with our DNA-based NGS approach. We also retrieved all relevant molecular data on other tested biomarkers.

Results

A total of n = 2173 advanced stage solid tumor patients were tested. Overall, at least one DNA-based alteration was detected in 52.7%, 66.6%, 87.6%, 68.8%, 46.7% of NSCLC ADC, CRC, GIST, melanoma, and breast cancer cases.

Conclusions

The present study has provided a real-world practice experience on the efficiency of applying DNA-based NGS analysis to both tissue and liquid biopsy samples in detecting actionable mutations in advanced stage solid tumor patients.